Cyclodextrins (CyDs) are cyclic oligosaccharides consisting of usually six, seven or eight glucose units, and are capable of forming inclusion complexes with various guest molecules in aqueous solution and in solid state. [1] [2] [3] [4] Since this molecular encapsulation leads to changes in physicochemical and biological properties of guest molecules, CyDs are successfully utilized as a drug carrier for improvements in aqueous solubility, chemical and physical stability and bioavailability, etc. of drugs in pharmaceutical fields.
Theoretical
1. The Binary Drug/CyD or Competitor/CyD System: The initial straight line of A L or B S type phase solubility diagrams can be described as Eqs. 1 and 2 for the drug/CyD system and the competitor/CyD system, respectively. These equations are the same as that used for determination of the ordinary 1 : 1 stability constant of CyD complexes from the initial straight line portion of phase solubility diagrams, K C ϭslope/S 0 (1Ϫslope). 10) (1) [Drug] [CyD] The solubility analysis of the ternary drug/competitor/CyD systems may be particularly useful for determination of the stability constant of a drug whose physicochemical and spectroscopic analyses are difficult, because they can be calculated by monitoring the solubility change of a competitor, without monitoring that of a drug. Furthermore, the present results suggest that attention should be paid to the type of the phase solubility diagram, as well as the magnitude of the stability constant and the solubility of the complex, for a rational formulation design of CyD complexes. (2) In Eqs. 2. The Ternary Drug/Competitor/CyD System: The solubility-and inclusion-equilibria for the ternary system can be described as shown in Chart 1, where the interaction between a drug and a competitor is assumed to be negligible. The total concentrations of drug, competitor and CyD are represented by Eqs. 5, 6 and 7.
[
The combination of Eqs. 5 and 7 gave Eq. 8 and that of Eqs. 6 and 7 gave Eq. 9. Equations 8 and 9 represent the solubility changes of a drug and a competitor as a function of CyD concentration in the ternary system.
3. The Multiple Drug/Competitors/CyD System Consisting of n Components: The solubility changes of a drug and an i-th competitor as a function of CyD concentration can be expressed by Eqs. 10 and 11: (10) (11) where [CA iϩ1 ] t , S iϩ1 and K iϩ1 are the solubility of the (iϩ1)th competitor in the presence of CyD, the intrinsic solubility of the (iϩ1)th competitor in the absence of CyD, and the stability constant with the (iϩ1)th competitor.
Equations 1, 2, 8-11 indicate that the solubilities of a drug and competitors increased linearly as a function of CyD concentration. The stability constant of one complex can be calculated from the slope of the initial straight line portion in the multi-component system, if the stability constants of other complexes are known. In the ternary drug/competitor/ CyD system, for example, the stability constant of a drug can be calculated by monitoring the solubility change of a competitor, without monitoring that of a drug, and by analyzing the initial linear solubility-increase of a competitor according to Eq. 9. Similarly, the stability constant of a competitor can be determined by monitoring the solubility change of a drug in the ternary system. Ϫ2 M, respectively. The K C values were 182(Ϯ3) M Ϫ1 and 312(Ϯ5) M Ϫ1 for the former and latter complexes, respectively, as shown in Table 1 . In the case of the ternary phenacetin/m-BBA/b-CyD system, the slopes of the solubility diagrams decreased, when compared with those of the corresponding binary systems. The decreasing degree of slopes was greater for phenacetin than m-BBA, because the stability constant of phenacetin is smaller than that of m-BBA, and thus the former complex was greatly affected by the competitive inclusion. The intrinsic solubility of each guest was not changed by the addition of the second guest, indicating a negligible interaction between phenacetin and m-BBA. The K 1 value of the phenacetin complex was calculated to be 186(Ϯ5) M Ϫ1 from the solubility change of m-BBA in the ternary system (᭡ in Fig. 1) , with using Eq. 9. This value was in good agreement with the stability constant (K C ϭ182 M
Results and Discussion

Ϫ1
) determined from the data of the binary system [CA ] [CyD] where
[CyD] where (᭺ in Fig.1 ) with using Eq. 1 (see Table 1 ). In the same way, the K 2 value of the m-BBA complex was calculated to be 316(Ϯ4) M
, using the data of the solubility change of phenacetin (᭹ in Fig. 1 ). This value coincided with that determined from the data of the binary system (᭝ in Fig.1 ) with using Eq. 2. The apparent solubilities of phenacetin and m-BBA in the presence of b-CyD fell well on the simulated line drawn according to Eqs. 8 and 9, supporting the equilibria of Chart 1A. Figure 2 shows the phase solubility diagrams of binary phenacetin/b-CyD, binary o-TA/b-CyD and ternary phenacetin/o-TA/b-CyD systems in phosphate buffer (pH 3.5). Although the pH of the o-TA systems (pH 3.5) was different from that (pH 4.5) of the m-BBA systems, phenacetin showed no change in its intrinsic solubility between the pHs, because phenacetin is a neutral compound. o-TA is known to form the inclusion complex with b-CyD in a molar ratio of 1 : 1 in aqueous solution, 9) but it showed a typical B S type phase solubility diagram. Therefore, the solubility-and inclusion-equilibria for the ternary system can be described as Chart 1B, where one of the complexes precipitates as a solid complex at higher CyD concentrations, i.e., a combination of A L and B S type solubility diagrams. The intrinsic solubility of each guest (i.e., in the absence of CyDs) was not changed by the addition of the another guest molecules, indicating a negligible interaction between phenacetin and o-TA. The stability constants of the phenacetin/b-CyD complex and the o-TA/b-CyD complex were calculated by using the data of the initial straight line portions of the diagrams, in the same way as described above. The stability constants were as follows: Table 1 ) determined from the binary system. The observed solubility changes of phenacetin and o-TA in the initial straight line portion were quantitatively reproduced by using Eqs. 8 and 9, supporting the equilibria of Chart 1B.
o-TA showed B S type solubility diagrams in both binary and ternary systems, but the plateau region of the ternary system shifted to higher b-CyD concentrations, compared with the binary system. This is because larger amounts of bCyD are necessary for the o-TA/b-CyD complex to reach its saturated solubility (about 2.3ϫ10 Ϫ2 M when expressed in o-TA concentration, Fig. 2 ), because the slope of the initial straight lines was smaller for the ternary system than the binary system. The analysis of the length of plateau regions by the method of Higuchi It is of interest to note that a plateau region appeared in the solubility diagram of the ternary phenacetin system, in spite of the fact that phenacetin gave originally the A L type diagram with b-CyD, i.e., a linear solubility increase, under the host concentration range. The plateau region of the ternary phenacetin system appeared in the same concentration range of b-CyD as that of the ternary o-TA system, and the length was exactly the same between the phenacetin and o-TA systems. After the plateau region, the solubility of phenacetin increased linearly with the slope (slopeϭ0.51) similar with that (slopeϭ0.52) in the absence of o-TA. These phenomena can be explained as follows: the o-TA/b-CyD complex begins to precipitate when b-CyD concentration reaches the point a (see Fig. 2 ). Between the points a and b, the added bCyD is consumed for the conversion of the remaining solid o-TA to its b-CyD solid complex. Therefore, the concentration of b-CyD is constant between the point a and b, and thus there was no increase in the phenacetin solubility, i.e., a plateau region. After the plateau, the added b-CyD is exclusively utilized for a formation of the phenacetin/b-CyD complex, thus the solubility of phenacetin increases with the slope similar as that in the absence of the competitor.
The present data indicated that the solubility change of CyD complexes can be estimated by using the stability constants of the complexes and intrinsic solubilities of the additives in formulations, when all components give A L type phase solubility diagrams. However, when one or several components in formulations exhibit B S type diagrams with CyD, they may affect not only the solubilization of CyD but also the type of solubility diagram. Therefore, attention should be paid to the type of the phase solubility diagram, as well as the magnitude of the stability constant and the solubility of the complex, for rational formulation design of CyD complexes. Furthermore, the solubility analysis of the ternary drug/competitor/CyD systems may be useful for determination of the stability constant of a drug whose physicochemical and spectroscopic analyses are difficult, because they can be calculated by monitoring the solubility change of a competitor, without monitoring that of the drug.
